What hormone therapy does inside a brain cell, and whether it shows up in a woman's life.
A woman at fifty-two asks her doctor whether hormone therapy will protect her memory. It is a fair question and a genuinely hard one. Twenty years of trials and cohort studies have narrowed it considerably, and we now know that when a woman starts treatment matters a great deal. What is still missing is the biology underneath, which no one can see from the outside.
That biology is what we have spent almost two decades on. Take tibolone, a drug millions of women already take for menopausal symptoms. We can now say what it does inside a brain cell. It lifts the mitochondrial machinery that moves and burns fuel, it holds the cell's energy balance through a crisis that would otherwise kill it, and it works through the estrogen receptors. That level of detail is what decides whether a hormone therapy protects a brain or simply passes through it.
A mechanism is only worth something once it meets people, which is why we work inside the studies where it can be tested. When a randomised trial gave a compound to people at elevated risk of dementia (Borda et al., 2024), we read the inflammation in their blood, asking who responded and why. Clinical and population studies are very good at finding the signals that matter. We are often able to say what sits behind them. Put the two together and an association becomes something we can act on.
Menopause is not a single event, and that is what makes it hard. It is a stretch of years in which hormones fall, metabolism shifts, inflammation rises and blood vessels change, all at once and in the same women. Something in there shapes what happens to memory, and much of it is along for the ride. We follow the metabolic and inflammatory signals across that window and ask which ones track the path a woman's brain health actually takes, whether they behave differently in women on hormone therapy, and whether they look the same in men. Every one of those questions comes straight from the bench.
Mechanism first, then people, then back to the bench with what we learned. That circuit is slow, and it is the only way we know to turn a molecule into something a doctor can eventually use.
